AAV2-ITR-pEFS-NLS_hfCas13d(RfxCas13d_N2V8)_FLAG_NLS-pA-U6-DR-Pcsk9-sg5-DR-Pcsk9-sg6-DR-AAV2-ITR Citations (1)

Originally described in: High-fidelity Cas13 variants for targeted RNA degradation with minimal collateral effects.
Tong H, Huang J, Xiao Q, He B, Dong X, Liu Y, Yang X, Han D, Wang Z, Wang X, Ying W, Zhang R, Wei Y, Xu C, Zhou Y, Li Y, Cai M, Wang Q, Xue M, Li G, Fang K, Zhang H, Yang H Nat Biotechnol. 2022 Aug 11. pii: 10.1038/s41587-022-01419-7. doi: 10.1038/s41587-022-01419-7. PubMed Journal

---

Articles Citing AAV2-ITR-pEFS-NLS_hfCas13d(RfxCas13d_N2V8)_FLAG_NLS-pA-U6-DR-Pcsk9-sg5-DR-Pcsk9-sg6-DR-AAV2-ITR

Articles
Gene therapy for ocular hypertension using hfCas13d-mediated mRNA targeting. Chen S, Liu Z, Lo CH, Wang Q, Ning K, Zhang Q, Zhao J, Shen Y, Sun Y. PNAS Nexus. 2025 Jun 17;4(6):pgaf168. doi: 10.1093/pnasnexus/pgaf168. eCollection 2025 Jun. PubMed

If you have published an article using this material, please email us at to have your article added to this page.